Alzheimer’s disease is the sixth-leading cause of death in the U.S.¹

Alzheimer’s disease is a degenerative brain disease. Over the course of the disease, it causes a decline in cognitive skills, affects a person’s ability to perform basic functions like walking and swallowing, and is ultimately fatal. The brain changes associated with Alzheimer’s disease may begin 20 or more years before symptoms appear. No current therapy slows or stops the damage to neurons that causes Alzheimer’s disease symptoms and eventually makes the disease fatal.¹

Currently, someone in the U.S. develops Alzheimer’s disease every 65 seconds.¹

By 2050, someone in the U.S. will develop Alzheimer’s disease every 33 seconds.¹

In the U.S.:

18.4 billion
Hours of unpaid care provided to Alzheimer’s disease + dementia patients in 2017¹

5.8 million
2018

7.2 million
2021

Projected number of people 65+ with Alzheimer’s disease is growing¹

1 Alzheimer’s Association, 2018 Alzheimer’s Disease Facts & Figures
M-AD-US-00991
Biogen is Pursuing Treatments for Alzheimer’s Disease

Biogen is one of the world’s oldest independent biotechnology companies and is developing investigational therapies with the goal of making new treatments available to patients.

Biogen has multiple investigational treatments currently in clinical trials.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aducanumab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E2609^2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAN2401^2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB076</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB092</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB080 (IONIS-MAPTRx)^4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Biogen is conducting clinical trials at 118 sites across 32 states^3*

To learn more about a Biogen trial in your area, please visit: https://www.engageandemerge.com/
Or call: (877) 231 - 7271

*Patients must meet all study criteria to participate in a clinical trial

^2 In collaboration with Eisai Co., Ltd.
^3 As of June 2018
^4 In Collaboration with Ionis Pharmaceuticals